Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Erbitux cetuximab IMC-C225: Phase II

IMCLE partner Merck KGaA (FSE:MRK, Darmstadt, Germany) presented data from a Phase II trial that showed 22.9% of patients given irinotecan plus Erbitux

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE